PRO-04 / Prothix - LARVOL DELTA

Inhibition of thermal formation of advanced glycation end products and acrylamide by gluten-bound betulonic acid and alphitolic acid: Mechanistic insights from spectroscopy and computation. (PubMed, Food Res Int) - "Molecular dynamics simulations further corroborated AA's binding stability within the gluten matrix, characterized by sustained interactions localized at residues Pro104, Tyr94, and Gln98. Collectively, these results delineate a mechanism whereby AA, by modulating gluten structure and potentiating its antioxidative defense system, effectively mitigates the formation of deleterious compounds in thermally processed foods, thereby advancing natural strategies for enhancing food safety and nutritional integrity."

Journal

PHD1-dependent hydroxylation of RepoMan (CDCA2) on P604 modulates the control of mitotic progression. (PubMed, Elife) - "In the accompanying paper (Jiang et al., 2025), we report development of a mass spectrometry-based method to reliably identify proline hydroxylation (OH-Pro) sites on proteins and use this to identify a PHD-dependent OH-Pro modification at Pro604 on the protein RepoMan (CDCA2), a regulatory subunit for protein phosphatase PP1γ with important roles in mitotic progression and cell viability...Moreover, analyses in both fixed and live cells released from a prometaphase arrest show that expression of the RepoMan-P604A mutant delays completion of mitosis, results in defects in chromosome alignment and segregation, and increases levels of cell death. These data support a role for PHD1-mediated prolyl hydroxylation in controlling progression through mitosis, acting, at least in part, via hydroxylation of RepoMan at P604 regulating the interaction of RepoMan with PP2A during chromosome alignment and thereby controlling the levels of Histone H3 phosphorylation at Thr3."

Journal • PPP2R5C

PRO 04 - Benign Radiotherapy: Back to the Future (ASTRO 2024) - "The presenters will be two high volume community radiation oncologists that treat benign conditions and an academic physician that will discuss RT for functional/CNS disorders. We will also discuss treatment techniques, how to build a program and how to market the program."

CNS Disorders • Immunology • Musculoskeletal Diseases • Oncology • Osteoarthritis • Pain • Rheumatology

PRO 04 - PRO: Updates in Lung Cancer Management (ASTRO 2023) - "This session will cover 4 main topics: 1) The current standard of care for management of stage III non small cell lung cancer, 2) Palliation of common issues such as hemoptysis, airway obstruction, and chest pain. 3) Management of patients ineligible for chemotherapy due to poor performance status/comorbidities 4) Comparison and contrast of volume definition in small cell lung cancer, prior to chemotherapy initiation, during chemotherapy (Cycle 2 or later, and as consolidation after initial course of chemotherapy for extensive stage is complete."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor

PRO 04 - PRO: Socioeconomic Session 1) Career Advancement for the Physician in Healthcare Organizations 2) Socioeconomic Update (ASTRO 2022) - "Attendees will also be updated on the status of Alternative Payment Models and on socioeconomic changes for 2023. To participate in Q&A or polls go to www.astro.org/AMSocialQA.Develop a deeper appreciation of the challenges, knowledge and skill sets needed to lead one's practice in this changing practice environment.Demonstrate an understanding of the upcoming and current socioeconomic and coding and coverage issues related to radiation oncology."

Oncology

A Low-Activity Polymorphic Variant of Human NEIL2 DNA Glycosylase. (PubMed, Int J Mol Sci) - "Arg103 is located in a long disordered segment within the N-terminal domain of hNEIL2, while Pro304 occupies a position in the β-turn of the DNA-binding zinc finger motif. The P304T variant was also less proficient than the wild-type, or R103W hNEIL2, in the removal of damaged bases from single-stranded and bubble-containing DNA. Overall, hNEIL2 P304T could be worthy of a detailed epidemiological analysis as a possible cancer risk modifier."

Journal • Oncology

[VIRTUAL] PRO 04 - Lung Cancer: Case Based Discussion (ASTRO 2021) - "Be sure to log in. To participate in Q&A or polls go to www.astro.org/AMSocialQA Explain best practice in the use of stereotactic ablative body radiation for treatment of early stage lung cancer; analyze how to approach challenging situations such as central tumors Discuss contemporary radiation approaches in the treatment of stage III NSCLC; determine how to approach tumors in close proximity to critical structures."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

[VIRTUAL] PRO 04 - Gastrointestinal Cancer: Case Based Discussion (ASTRO 2020) - "Explain and discuss rationale for outlining radiation target volumes for upper and lower GI malignancies. Analyze recently published data and discuss ongoing trials in the management of GI cancers."

Clinical • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Oncology • Pancreatic Cancer • Rectal Cancer • Solid Tumor

The Hydroxyproline Proteome of HeLa cells with Emphasis on the Active Sites of Protein Disulfide Isomerases. (PubMed, J Proteome Res) - "Fifteen of the sites probably contain 4R-hydroxyproline (Pro30 of Serpin H1, Pro520 of Aspartyl/asparaginyl beta-hydroxylase, Pro223 of Neutral alpha-glucosidase AB, Pro977 of Hypoxia up-regulated protein 1, Pro378 of Protein ERGIC-53 and Pro252 of Protein CASC4, Pro545 of Bromodomain-containing protein 2, Pro488 of Bromodomain-containing protein 3, Pro130 of Nucleolar RNA helicase 2, Pro51 of PDIA1, Pro395 of PDIA1, Pro404 of PDIA3, Pro89 of PDIA4, Pro204 of PDIA4 and Pro553 of PDIA4). The remaining sites could be either 4R-hydroxyproline or 3S-hydroxyproline. Recommendations are made to improve automated interpretation of proteomic data to enhance future proteomic research whose goal is to mine more of the remaining dark matter of the proteome."

Journal

PRO 04 - (INTERACTIVE) Clinical Cases in Gynecologic Oncology (ASTRO 2019) - "Apply current guidelines in radiation therapy of cervix and endometrial cancer to clinical practice3. Discuss and analyze relevant clinical trial data pertaining to the management of cervix and endometrial cancer"

Clinical